2018第十届DIA中国年会

Menu Back to 10th-DIA-China-Annual-Meeting

概览

转眼瞬间已九载，凝神常思向十年。2018年，DIA中国年会将迎来10周岁。

十年前，当中国尚未全面参与国际多中心临床试验时，DIA来到中国，在北京主办召开了以“从‘平坦世界’的视角看药物研发：创新、法规和全球化”为主题的第一届中国年会。自2009年首届年会以来，DIA在中国的十年，是见证中国医药风雨兼程地从传统制药走向自主创新的十年，是中国医药健康产业蓬勃发展的十年，也是见证中国药监改革快速发展硕果累累的十年。刚刚过去的两年中，国家食品药品监督管理局（CFDA）已经展示了前所未有的决心，推出了一系列措施深化制度改革，确保公众用药的有效性与安全性。

2017年5月21日，在上海国际会议中心举办的第九届DIA中国年会上，CFDA--DIA联合举办的有关ICH的研讨会向世界传递了来自中国的坚定的声音。2017年6月，CFDA正式加入ICH标志了中国药监历史上的一个重要的里程碑。

2018年，第十届DIA中国年会，DIA亚洲最大的跨学科盛会，您是否想参加？您是否想在中国生命科学创新如此激动人心的时刻为非凡事件贡献一份力量？

第十届 DIA 中国年会设有壁报展览。这是一个交流知识和经验，应用新技术和新方法的良机。

精选主题

开幕特别论坛
监管科学
CFDA专场
创新性突破治疗（肿瘤、心血管疾病等）
临床开发（运营、基地、GCP等）
定量科学
CMC及仿制药
生物制品及生物类似物开发
医学事务
药物安全与药物警戒
患者参与
医疗健康的大数据研究与人工智能
医疗器械、伴随诊断、IVD
热点话题（罕见病、心血管领域多方合作、投资与商务拓展、Portfolio管理、支付方等）

项目委员会

Pei HU • Director, Phase I Unit, Clinical Pharmacological Research Center
Peking Union Medical College, China
Bin Xue • Director-General
China Center for Food and Drug International Exchange, CFDA, China
Wendy Yan, MD, MBA • Senior Vice President, Head of Regulatory Affairs
BeiGene (Beijing) Co., Ltd., China
Irene Deng • Head of Regulatory Affairs, China
Sanofi, China
Jin Cui • Program Officer
China Center for Food and Drug International Exchange , China
George LIU • Head of Early Development and Scientific Operation
Harbour Biomed, China
Zhiqiang Ning • Vice President, Research & Clinical Development
Shenzhen Chipscreen Biosciences, Ltd., China
Jessica Liu, MD • VP
TIGERMED CO.,LTD., China
Sunny Zhu • Chief Medical Officer, Infectious Diseases
Everest Medicines, China
Hannah Chen, MD • Former Director, CQA/PV China, Jansen Pharm R&D QA
Johnson & Johnson, China
Paul Dai, MD • Head of Clinical Operations
TDC, Asia, Takeda, China
Reako Ren • Head of SMO Services
WuXi Apptec., China
Connie DAI •
Harbour Biomed, China
Hualong Sun • General manager
Meta Clinical Technical Co. Ltd, China
Charles Yan • Vice President, Head of Clinical Data Science Center
Jiangsu Hengrui, China
Melly Lin • Senior Regulatory Manager, CMC Policy,
Roche(China) Holding Ltd, China
Joe Zhang • Co-founder and CEO
BJ Bioscience Inc., China
Xiangyang Zhu • CEO
Shanghai Huaota Biopharma Co., Ltd, China
Li L Wang • Senior Vice President, Lilly China Drug Development and Medical Affairs Center
Eli Lily & Company, China
Xiaoling Wang • Clinical Documentation
Clinical Science Operation, Sanofi R&D China, China
Xue TANG • Drug Safety Unit Regional Head (DRH),
APAC Pfizer, China
Dayao ZHAO, MD, PhD • Former Vice President and Lead, China Drug Development
Pfizer, China
Jane Y. Cai, PhD • Former Managing Director
DIA China, China
Tony Guo • Executive Director, Head of Biometrics China
BeiGene, China
Tong Guo • Vice President and Head of Sales
Greater China IQVIA, China
Amber Wang • Vice President, Regulatory Affairs & QA
SmithNephew, China
Ruyi He, MD • Chief Scientist
Center for Drug Evaluation, CFDA, United States
Jingsong Wang, MD • Chief Executive Officer
Harbour Biomed, China
Shun Lu • Director, Center for Clinical Medicine of Lung Cancer
Shanghai Chest Hospital, Shanghai Jiaotong University, China
Xianglin Zhang • President
Shenyang Pharmaceutical University, China
Carol Zhu, MBA • Advisory
DIA Advisory Members, China
Ron Fitzmartin, PhD, MBA • Senior Informatics Advisor, Office of the Director, CBER
FDA, United States
Murray M. Lumpkin, DIAFellow, MD, MSc • Deputy Director, Regulatory Affairs, Lead Global Regulatory Systems Initiatives
Bill and Melinda Gates Foundation, United States
Kenneth A. Getz, MBA • Deputy Director, Research Professor
Tufts Center For the Study of Drug Development, United States
Sandra A. Milligan, JD, MD • Senior Vice President, Head of Global Regulatory Affairs and Clinical Safety
Merck & Co., Inc., United States
Ling Su, PhD • Professor
Shenyang Pharmaceutical University, China